Skip to main content
. 2022 Feb 4;14(3):802. doi: 10.3390/cancers14030802

Figure 1.

Figure 1

Difference in PFS between bevacizumab-treated patients who switched to RAS wild-type in plasma vs. patients who remained RAS mutant.